UCB PHARMA SA has a total of 1,444 patent applications. It decreased the IP activity by 52.0%. Its first patent ever was published in 1999. It filed its patents most often in United Kingdom, WIPO (World Intellectual Property Organization) and United States. Its main competitors in its focus markets pharmaceuticals, biotechnology and organic fine chemistry are SHIRE ORPHAN THERAPIES GMBH, PROTEOLIX INC and BIOGEN INC.
# | Country | Total Patents | |
---|---|---|---|
#1 | United Kingdom | 203 | |
#2 | WIPO (World Intellectual Property Organization) | 155 | |
#3 | United States | 141 | |
#4 | EPO (European Patent Office) | 133 | |
#5 | China | 101 | |
#6 | Australia | 89 | |
#7 | Canada | 81 | |
#8 | Republic of Korea | 51 | |
#9 | Brazil | 47 | |
#10 | Israel | 45 | |
#11 | Japan | 41 | |
#12 | Hong Kong | 38 | |
#13 | Mexico | 34 | |
#14 | Singapore | 34 | |
#15 | EAPO (Eurasian Patent Organization) | 30 | |
#16 | Taiwan | 19 | |
#17 | New Zealand | 18 | |
#18 | South Africa | 16 | |
#19 | Argentina | 15 | |
#20 | Norway | 13 | |
#21 | Colombia | 12 | |
#22 | Chile | 11 | |
#23 | Malaysia | 11 | |
#24 | Hungary | 10 | |
#25 | Ukraine | 10 | |
#26 | Morocco | 9 | |
#27 | Peru | 9 | |
#28 | Tunisia | 9 | |
#29 | Serbia | 7 | |
#30 | India | 6 | |
#31 | African Regional Industrial Property Organization | 5 | |
#32 | Luxembourg | 4 | |
#33 | Poland | 4 | |
#34 | Czechia | 3 | |
#35 | Ecuador | 3 | |
#36 | Iceland | 3 | |
#37 | Philippines | 3 | |
#38 | Uruguay | 3 | |
#39 | Dominican Republic | 2 | |
#40 | Georgia | 2 | |
#41 | Lithuania | 2 | |
#42 | Montenegro | 2 | |
#43 | Netherlands | 2 | |
#44 | Slovenia | 2 | |
#45 | Slovakia | 2 | |
#46 | Belgium | 1 | |
#47 | Bulgaria | 1 | |
#48 | Cuba | 1 | |
#49 | Germany | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology | |
#3 | Organic fine chemistry | |
#4 | Measurement | |
#5 | Medical technology | |
#6 | Environmental technology |
# | Technology | |
---|---|---|
#1 | Therapeutic chemical compounds | |
#2 | Peptides | |
#3 | Medical preparations | |
#4 | Heterocyclic compounds | |
#5 | Microorganisms | |
#6 | Analysing materials | |
#7 | Fermentation | |
#8 | Syringes | |
#9 | Acyclic or carbocyclic compounds | |
#10 | Climate change mitigation in goods production |
# | Name | Total Patents |
---|---|---|
#1 | Humphreys David Paul | 161 |
#2 | Popplewell Andrew George | 127 |
#3 | Adams Ralph | 117 |
#4 | Lawson Alastair David Griffiths | 96 |
#5 | Brookings Daniel Christopher | 78 |
#6 | Langham Barry John | 61 |
#7 | Tyson Kerry Louise | 59 |
#8 | Fanara Domenico | 54 |
#9 | Ellis Mark | 49 |
#10 | Neuss Judi Charlotte | 46 |
Publication | Filing date | Title |
---|---|---|
JP2016020396A | Antibodies to ion channels | |
CN105814052A | Imidazopyridine derivatives as modulators of TNF activity | |
GB201407948D0 | Method | |
GB201406894D0 | Proteins | |
GB201405955D0 | Proteins | |
GB201405952D0 | Proteins | |
GB201405348D0 | Training cassette for auto-injector | |
GB201404384D0 | Method | |
GB201403915D0 | Proteins | |
GB201403914D0 | Proteins | |
GB201403913D0 | Proteins | |
GB201403912D0 | Proteins | |
CN105008360A | Therapeutically active pyrazolo-pyrimidine derivatives | |
GB201321739D0 | Therapeutic agents | |
GB201321745D0 | Therapeutic agents | |
GB201321734D0 | Therapeutic Agents | |
GB201321744D0 | Therapeutic agents | |
GB201321729D0 | Therapeutic agents | |
GB201321738D0 | Therapeutic Agents | |
GB201321741D0 | Therapeutic agents |